Clinical Data's PGxHealth division announced this week that it is doubling the number of genes detected by its Familion Long QT Syndrome Test to 10 genes. The test helps guide treatment for sudden cardiac death.
The company also announced it has filed a patent application with the United States Patent and Trademark Office pertaining to 336 new mutations in the long QT genes.